Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms.

Optimizing Cholesterol Treatment in Patients with Muscle Complaints / R.S. Rosenson, M. Banach, K.M. Borow, L.T. Braun, E. Bruckert, L.R. Brunham, A.L. Catapano, M.B. Elam, J. Mancin, P.M. Moriarty, P.B. Morris, P. Muntner, K.K. Ray, P.E.S. Stroes, B.A. Taylor, V.H. Taylor, G.F. Watts, P.D. Thompson. - In: JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY. - ISSN 0735-1097. - 70:10(2017 Sep 05), pp. 1290-1301. [10.1016/j.jacc.2017.07.752]

Optimizing Cholesterol Treatment in Patients with Muscle Complaints

A.L. Catapano;
2017

Abstract

Statins are highly effective for preventing cardiovascular events by reducing low-density lipoprotein cholesterol (LDL-C). However, many patients taking statins report muscle-related symptoms that prevent the use of guideline recommended doses. Patients with reported intolerance to statins have a high risk of cardiovascular events. Clinical strategies that optimize cardiovascular risk reduction through LDL-C lowering need to be applied in patients experiencing intolerable side effects that they attribute to statins. In this paper, the authors review definitions of statin intolerance, propose algorithms to better define statin intolerance, and describe approaches to optimize cardiovascular risk reduction among individuals reporting statin-associated muscle symptoms.
cardiovascular disease; low-density lipoprotein; myalgia; myopathy; statin intolerance; anticholesteremic agents; cardiovascular diseases; cholesterol; humans; hydroxymethylglutaryl-coa reductase inhibitors; muscle, skeletal; muscular diseases; risk factors; cardiology and cardiovascular medicine
Settore BIO/14 - Farmacologia
5-set-2017
Article (author)
File in questo prodotto:
Non ci sono file associati a questo prodotto.
Pubblicazioni consigliate

I documenti in IRIS sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.

Utilizza questo identificativo per citare o creare un link a questo documento: https://hdl.handle.net/2434/548958
Citazioni
  • ???jsp.display-item.citation.pmc??? 46
  • Scopus 143
  • ???jsp.display-item.citation.isi??? 134
social impact